Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS INC (REGN), sold 34,853 shares at $306.37 ($10.6M) on 2019-05-14, disclosed to the SEC on 2019-05-15.
Open-market sale of $10.6M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $304.20 | 15,147 | $4.6M | 43.3% |
| 2 | $305.43 | 6,575 | $2.0M | 18.9% |
| 3 | $305.43 | 6,575 | $2.0M | 18.9% |
| 4 | $306.37 | 3,278 | $1.0M | 9.4% |
| 5 | $306.37 | 3,278 | $1.0M | 9.4% |
| Total | $305.07 avg | 34,853 |
| $10.6M |
| 100% |
| Filing → |
| REGN | SELL | 2023-08-23 | $19.6M | — | Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |